Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

AstraZeneca reaches a record high in the UK stock market, buoyed by strong earnings and a U.S. drug-pricing deal. Meanwhile, ...

NYSE:PFE Earnings and Revenue History November 11th 2025 How Do Unusual Items Influence Profit? To properly understand Pfizer ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

“Pfizer beat the numbers and people just yawned. Oh my god the group is so challenged. “But we’re looking for that big win ...

Stock futures are sharply higher amid hopes that the U.S. government shutdown could end soon, while investors prepare for a ...

Pfizer Inc. (NYSE:PFE) is one of the stocks highlighted as Jim Cramer responded to questions from Harvard Business School ...

Pfizer Inc. is rated a Buy with stable guidance, robust pipeline, strong free cash flows & appealing dividend yield. Learn ...

Pfizer (NYSE: PFE) beat earnings expectations decisively this morning, posting adjusted EPS of $0.87 against a $0.64 ...

Pfizer revenue trends remained uneven in the third quarter, the company exhibited "continued cost discipline," according to ...

Pfizer’s Q3 2025 earnings fell despite beating estimates. Weak growth and a stagnant outlook keep PFE stock a Hold.